Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.76 +0.56 (+2.14%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗
Durability, not yield, is the deciding factor. 
Via The Motley Fool
News headline image
Avascular Necrosis Market Size, Industry Share By 2035 ↗
The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, 
Via Talk Markets
Topics Economy
News headline image
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
These stocks pay between 4.2% and 6.7% in dividends. 
Via The Motley Fool
News headline image
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗
Whichever one you choose, you'll need patience before you can see solid returns. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 ↗
It is finally bouncing back after several challenging years. 
Via The Motley Fool
News headline image
3 Large-Cap Stocks with Solid Fundamentals
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit... 
Via StockStory
News headline image
How to Recession-Proof Your Retirement Before the Second Half of 2026 ↗
You should consider these strategies if you can't afford to wait out another market crash. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
3 Dividend Stocks to Buy and Hold Forever ↗
These aren't the most exciting businesses, but they have a lot to offer to long-term investors. 
Via The Motley Fool
News headline image
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
This little-discussed pipeline program could prove to be a big success. 
Via The Motley Fool
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed? ↗
Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence. 
Via The Motley Fool
Topics Economy
News headline image
1 Healthcare Stock with Promising Prospects and 2 We Find Risky
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a... 
Via StockStory
News headline image
3 Cash-Producing Stocks Worth Your Attention
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ... 
Via StockStory
News headline image
Is Pfizer Stock a "Value Trap" or a Generational Opportunity? ↗
Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before. 
Via The Motley Fool
Topics Intellectual Property
News headline image
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers ↗
Pfizer said Sunday its Braftovi-tied regimen nearly doubled the time colon cancer patients lived without getting sicker. 
Via Investor's Business Daily
Topics Stocks
News headline image
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Thriving in the Age of Overwhelm ↗
Why do so many people feel overwhelmed right now? And what can investors do about it? 
Via The Motley Fool
News headline image
Why Wall Street Is Dead Wrong About This Popular Stock ↗
Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Addiction Treatment Market Size, Demand, Growth By 2035 ↗
The most recent research report on the "Addiction Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts 
Via Talk Markets
Topics Economy
News headline image
Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies ↗
Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally. 
Via Benzinga
News headline image
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
From Pfizer Inc.
Via Business Wire
News headline image
Rituxan (rituximab) Drug Market Size, Share, Industry Growth By 2035 ↗
The most recent research report on the "Rituxan (rituximab) Drug Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore 
Via Talk Markets
Topics Economy
News headline image
Drugs for Oral Mucositis Market Size, Report Growth By 2035 ↗
The most recent research report on the "Drugs for Oral Mucositis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore 
Via Talk Markets
Topics Economy
News headline image
1 Stock Under $50 with Solid Fundamentals and 2 We Ignore
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
Topics Energy
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
D-Wave Quantum vs. IonQ: Which Quantum Computing Stock Is a Better Buy in 2026? ↗
Explore how two quantum innovators stack up on customer reach, financial health, and risk as they race for commercial leadership in a fast-evolving sector. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.